GlassScriptPhysician profile
Joan Russell Shepherd
NPI 1689838294
$2,666.07
in general payments reported to CMS, 2019-2025
24 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.44 · 2022: $79.78 · 2023: $29.06 · 2024: $766 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,553.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $461.37 | 2024-2025 | Caplyta |
| Abbvie INC. | $442.01 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $325.91 | 2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $246.95 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $184.72 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $177.28 | 2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Axsome Therapeutics, INC. | $172.60 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $148.21 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $124.74 | 2024 | Invega |
| Indivior INC. | $63.00 | 2022-2024 | Sublocade |
| Almatica Pharma LLC | $33.92 | 2024-2025 | Loreev Xr, Teriparatide |
| Teva Pharmaceuticals USA, INC. | $33.80 | 2025 | Uzedy, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $33.35 | 2025 | Quviviq |
| Neos Therapeutics, LP | $31.33 | 2024-2025 | Adzenys Xr-Odt |
| Tms Neurohealth Centers INC. | $25.12 | 2025 | Tms Neurohealth Centers INC. |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $22.70 | 2025 | |
| Gilead Sciences, INC. | $21.91 | 2022 | |
| Braeburn INC. | $20.21 | 2024 | Brixadi |
| Lundbeck LLC | $19.91 | 2025 | Abilify Asimtufii |
| Bausch Health US, LLC | $19.47 | 2021 | |
| Ironshore Pharmaceuticals INC. | $17.38 | 2024 | |
| Collegium Pharmaceutical, INC. | $17.08 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $12.97 | 2021 | |
| Corium, LLC | $10.13 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.